AU3202797A - Inactivation resistant factor viii - Google Patents

Inactivation resistant factor viii

Info

Publication number
AU3202797A
AU3202797A AU32027/97A AU3202797A AU3202797A AU 3202797 A AU3202797 A AU 3202797A AU 32027/97 A AU32027/97 A AU 32027/97A AU 3202797 A AU3202797 A AU 3202797A AU 3202797 A AU3202797 A AU 3202797A
Authority
AU
Australia
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32027/97A
Other languages
English (en)
Inventor
Kagehiro Amano
Randal J. Kaufman
Steven W. Pipe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU3202797A publication Critical patent/AU3202797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU32027/97A 1996-04-24 1997-04-24 Inactivation resistant factor viii Abandoned AU3202797A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US60016117 1996-04-24
US1778596P 1996-05-15 1996-05-15
US60017785 1996-05-15
PCT/US1997/006563 WO1997040145A1 (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Publications (1)

Publication Number Publication Date
AU3202797A true AU3202797A (en) 1997-11-12

Family

ID=26688196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32027/97A Abandoned AU3202797A (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Country Status (10)

Country Link
US (2) US6838437B2 (show.php)
EP (3) EP1754718B1 (show.php)
JP (2) JP3987114B2 (show.php)
AT (2) ATE502958T1 (show.php)
AU (1) AU3202797A (show.php)
CA (1) CA2252896C (show.php)
DE (2) DE69740154D1 (show.php)
DK (1) DK1754718T3 (show.php)
PT (1) PT1754718E (show.php)
WO (1) WO1997040145A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833848E (pt) * 1995-06-12 2002-01-30 Sanquin Bloedvoorziening Peptidos ligantes do factor ix derivados do factor viii e sua utilizacao como inibidores da coagulacao do sangue
ATE502958T1 (de) 1996-04-24 2011-04-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
WO2006067230A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
JP2008537680A (ja) * 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2520586A1 (en) * 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
WO2009156137A1 (en) 2008-06-24 2009-12-30 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
MX347503B (es) * 2010-11-05 2017-04-26 Baxalta Inc Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2768522B1 (en) 2011-10-18 2016-07-27 CSL Behring GmbH Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
IN2012CH03778A (show.php) * 2012-09-12 2015-04-24 Ct For Bioseparation Technology Vit
US9657111B2 (en) 2012-11-29 2017-05-23 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein C and uses thereof
BR112015012414A2 (pt) * 2012-11-29 2017-09-12 Bayer Healthcare Llc anticorpos monoclonais contra proteína c ativada (apc)
EP2988758B1 (en) * 2013-03-15 2018-04-25 Bayer HealthCare LLC Variant factor viii polypeptides and methods of their production and use
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016142289A1 (en) * 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Compounds for improving the half-life of von willebrand factor
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
KR20180006453A (ko) 2015-05-22 2018-01-17 체에스엘 베링 리컴비넌트 퍼실리티 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
US10808023B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated von Willebrand factor
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
EP3538134B1 (en) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CA3043250A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CA3159985A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
NZ236094A (en) 1989-11-17 1993-04-28 Chiron Corp Recombinant protein complex having human factor viii:c activity
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6456096A (en) 1995-07-11 1997-02-10 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
ATE502958T1 (de) 1996-04-24 2011-04-15 Univ Michigan Gegen inaktivierung resistenter faktor viii

Also Published As

Publication number Publication date
US20020132306A1 (en) 2002-09-19
JP3987114B2 (ja) 2007-10-03
JP4250661B2 (ja) 2009-04-08
EP0910628A1 (en) 1999-04-28
EP0910628B1 (en) 2006-03-08
DE69740154D1 (de) 2011-05-05
DE69735421T2 (de) 2006-10-19
US6838437B2 (en) 2005-01-04
EP1754718A2 (en) 2007-02-21
JP2000511407A (ja) 2000-09-05
EP0910628A4 (en) 2001-05-02
US7459534B2 (en) 2008-12-02
EP1754718B1 (en) 2011-03-23
CA2252896C (en) 2009-03-10
PT1754718E (pt) 2011-07-13
ATE319817T1 (de) 2006-03-15
EP1754718A3 (en) 2007-05-16
US20060014683A1 (en) 2006-01-19
ATE502958T1 (de) 2011-04-15
EP2202242A1 (en) 2010-06-30
DE69735421D1 (de) 2006-05-04
CA2252896A1 (en) 1997-10-30
JP2007228973A (ja) 2007-09-13
WO1997040145A1 (en) 1997-10-30
DK1754718T3 (da) 2011-07-18

Similar Documents

Publication Publication Date Title
AU3202797A (en) Inactivation resistant factor viii
AU5298293A (en) Chimeric factor viii
AU645539B2 (en) A recombinant human factor VIII derivative
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
CA2081659C (en) Recombinant human factor viii derivatives
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
EP0442961A1 (en) HYBRID PROCOAGULATING PROTEINS.
AU3498189A (en) Fibronectin binding protein
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
MX9708426A (es) Polipeptido hk2 de variante estable.
EP0627923A4 (en) THERAPEUTIC DOMAINS OF THE WILLEBRAND FACTOR.
EP0665888A4 (en) ALLERGEN FROM RAYGRASS POLLEN.
DE69132889D1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
MX9806041A (es) Proteina purificada sr-p70.
EP0576426A4 (show.php)
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
AU3711597A (en) A novel galanin receptor
AUPM772494A0 (en) Improvements in production of proteins in host cells
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
WO1995018828A1 (en) Factor viii derivatives